Novo Nordisk's Pill Pivot: Can Convenience Close the Valuation Gap?

Novo Nordisk bets on oral Wegovy to counter pipeline doubts, as shares lag 25% below record despite Q2 revenue growth and guidance upgrade.

The needle has defined Novo Nordisk's era of dominance. Now the Danish pharmaceutical giant is betting that shedding it entirely will define the next chapter. When the oral version of Wegovy reaches German pharmacies on September 1, 2026, it marks more than a product launch — it represents the company's most tangible answer to a market that has spent recent months questioning whether the growth story still holds.

The stakes are measurable in the share price. The stock traded at 40.81 euros on Friday, up 2.23 percent, hovering just above its 200-day moving average of 40.30 euros. Yet that leaves the equity roughly a quarter below its January record of 54.86 euros — a gap that investors increasingly read as a referendum on the pipeline, not the quarter.

A Quarter of Contradictions

The numbers Novo Nordisk posted for the second quarter of 2026 were, on their face, respectable. Adjusted revenue reached 78.488 billion Danish kroner, up 7 percent on a comparable basis, while adjusted operating profit climbed 11 percent to 33.389 billion kroner. Management also lifted its full-year guidance to a range of 0 to minus 6 percent growth, an improvement from the previous minus 4 to minus 12 percent.

But the market's reaction was less forgiving. A non-cash impairment of 6.3 billion kroner — tied largely to the pipeline candidate Monlunabant — clouded the operational picture. And the guidance revision, while technically an upgrade, still implies stagnation or contraction for the remainder of 2026. Independent analyst Edmund Ingham moved to a sell rating on Friday, pointing to precisely that tension.

The deeper problem sits with CagriSema, the combination therapy once seen as the company's next blockbuster. Goldman Sachs analyst James Quigley slashed his peak sales estimate for the drug from 11.8 billion to 5 billion dollars after mixed clinical data, downgrading the stock from buy to neutral in the process. Morningstar's Karen Andersen followed on Thursday, trimming her fair value estimate from 311 to 285 kroner on lower long-term margin assumptions and reduced CagriSema expectations.

The Oral Offensive

The pill strategy offers a counter-narrative. In the United Kingdom, where the oral Wegovy launched just weeks ago, Novo Nordisk reports a 90 percent market share and 300,000 patients within three weeks — evidence, the company argues, that removing the injection barrier can rapidly expand the addressable market.

Germany represents a sterner test. The country's reimbursement framework is more restrictive than Britain's, and the company has yet to secure cost coverage. There was a glimmer of progress on Friday: reports from Euractiv suggested Germany's health ministry is signaling a possible shift toward reimbursing weight-loss medications, a move France has already made. A positive decision would provide a meaningful sales catalyst in one of Europe's most important markets.

The company is also investing heavily in the pivot. Some 432 million euros are earmarked for Irish production facilities dedicated to oral medications, an acknowledgment that supply constraints — which plagued the injectable market for years — cannot be allowed to repeat. Chief Financial Officer Karsten Munk Knudsen emphasized the oral rollout's strategic centrality when presenting the quarterly figures.

Defending the Franchise

Legal battles run in parallel. In the Netherlands, a district court in The Hague issued a preliminary injunction on Thursday barring pharmacy Ceban Ziekenhuisfarmacie from distributing a compounded semaglutide nasal spray that infringed the company's supplementary protection certificate. In the United States, Novo Nordisk is pursuing litigation against Hims & Hers over compounded versions of its weight-loss drugs, while separately sparring with Eli Lilly over advertising claims related to dosing comparisons.

The regulatory winds may be shifting in the company's favor. The FDA is seeking to restrict bulk compounding of semaglutide, a move that could push many cheaper imitators off the market and potentially steer patients back to branded products.

The September Test

The immediate question is whether the oral launch can replicate its British success under German conditions — and whether the company can present a credible growth narrative beyond CagriSema at its capital markets day on September 21. The company has already bought back roughly 27 million B-shares for about 7.5 billion kroner through August 3, signaling management's confidence in the current valuation.

The structural headwinds are real. Reports indicate that list prices for Wegovy and Ozempic in the United States could fall by approximately 50 and 35 percent respectively from January 2027, tied to a most-favored-nation arrangement expanding Medicare Part D coverage. That would pressure margins in the company's largest single market.

For now, the stock sits in a narrow band around its 200-day line, consolidating without clear direction. The capital markets day will test whether management can convince investors that the pill — not the pipeline — is the growth engine that matters. The next hard data point after that arrives with the nine-month report on November 4, 2026. Until then, the gap between January's high and today's price is the market's way of saying the proof, for now, remains in the pudding.